Latest News - Retina

Friday, November 17, 2017 | Product Releases, Retina

Vortex Surgical Launches Innovative Convenience Kits

Vortex Surgical announced the release of the Vortex Surgical Convenience Kit. Launched during the annual meeting of the American Academy of Ophthalmology in New Orleans, the product is targeted a…

Read the full story

Monday, November 13, 2017 | Retina, Genentech

Genentech Makes Statement Following Release of Novartis' Brolucizumab Data

At the American Academy of Ophthalmology meeting in New Orleans, Novartis announced positive results from two phase 3 studies (HAWK and HARRIER) of brolucizumab versus Regeneron's aflibercept (Eyl…

Read the full story

Monday, November 13, 2017 | Clinical Trials, Retina, Novartis

Novartis: Brolucizumab (RTH258) Demonstrates Superiority Versus Aflibercept in Key Secondary Endpoint Measures of Disease Activity in nAMD

Novartis announced further positive results from two phase 3 studies of brolucizumab versus aflibercept (Eylea). Results showed noninferiority in primary endpoint, superiority in key retinal health ou…

Read the full story

Friday, November 10, 2017 | Clinical Trials, Retina, Spark Therapeutics

Three-year Follow-up Phase 3 Data Provide Additional Information on Luxturna in Patients with Biallelic RPE65-Mediated Inherited Retinal Disease

Spark Therapeutics announced new 3-year follow-up data from the continuing phase 3 trial of Luxturna (voretigene neparvovec), an investigational, potential one-time gene therapy for the treatment of p…

Read the full story

Wednesday, November 08, 2017 | Product Releases, Retina, OD-OS GmbH

OD-OS Announces New Framework for Remote Planning of Navigated Retinal Laser Treatments

OD-OS announced the upcoming release of NaviGATE - a new framework for remote planning of retinal treatments with the Navilas 577s navigated laser system. NaviGATE allows physicians to digitally pre-p…

Read the full story

Tuesday, November 07, 2017 | Conferences, Retina, Novartis

Novartis Pivotal Brolucizumab (RTH258) Data to be Presented at AAO

Novartis will be presenting more detailed results from its phase 3 studies (HAWK and HARRIER) of brolucizumab (RTH258) vs. aflibercept for the treatment of neovascular age-related macular degeneration…

Read the full story

Monday, October 30, 2017 | Product Releases, Retina, Allergan

Allergan Receives Approval for Ozurdex in China for the Treatment of Retinal Vein Occlusion

Allergan announced that it has received an imported drugs license from the Chinese Food and Drug Administration (CFDA) to market Ozurdex (dexamethasone intravitreal implant 0.7 mg) for the treatment o…

Read the full story

Friday, October 27, 2017 | Retina

Lin BioScience Receives FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease

Lin BioScience announced that the FDA has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. Stargardt Disease is caused by a mutation…

Read the full story

Wednesday, October 25, 2017 | Clinical Trials, Retina, Clearside Biomedical

Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with DME

Clearside Biomedical announced completion of patient enrollment in the phase 2 clinical trial (TYBEE) of CLS-TA, Clearside’s proprietary suspension formulation of the corticosteroid triamcinolon…

Read the full story

Thursday, October 19, 2017 | Clinical Trials, Retina, AMD, Genentech

Genentech Completes Patient Enrollment In Phase 2 Study Evaluating A New Delivery System for Lucentis

Genentech has completed enrollment in the LADDER (Long Acting Delivery of Ranibizumab) trial, a phase 2, multicenter, randomized, active treatment-controlled clinical trial investigatin…

Read the full story

Tuesday, October 10, 2017 | Clinical Trials, Medical Studies, Retina, ThromboGenics

ThromboGenics Announces Publication in Experimental Eye Research of Preclinical Data Supporting Therapeutic Potential of THR-317 in DR

ThromboGenics NV announced that preclinical data on its THR-317 have been published in Experimental Eye Research. ThromboGenics’ preclinical studies are designed to investigate inhibition of pla…

Read the full story

Friday, October 06, 2017 | Earnings & Financials, Retina, AMD

PanOptica Secures Funding to Advance Clinical Development of PAN-9080 Topical Anti-VEGF Eye Drop

PanOptica announced that it has secured $11 million in a Series B financing to enable clinical advancement of PAN-90806, a small molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop f…

Read the full story

Thursday, October 05, 2017 | Acquisitions/Mergers, Retina, Aerie Pharmaceuticals, AMD

Aerie Pharmaceuticals Announces Drug Delivery Asset Acquisition to Advance Its Retinal Disease Program

Aerie Pharmaceuticals announced that it has acquired rights to use Envisia Therapeutics' PRINT technology in ophthalmology and certain other assets. The PRINT technology is a proprietary system ca…

Read the full story

Tuesday, October 03, 2017 | Conferences, Retina, Alimera Sciences

Alimera Sciences Announces Four Data Sets for Iluvien to Be Presented at 2017 Retina Society’s Annual Meeting

Alimera Sciences announced that four Iluvien data sets will be presented during the 2017 Annual Meeting of the Retina Society to be held October 5-8 at the Fairmont Copley Plaza Hotel in Boston. &q…

Read the full story

Tuesday, October 03, 2017 | Medical Studies, Retina

Rapid Ascent to High Altitude Alters the Retina

Significant increases in retinal nerve fiber layer (RNFL) thickness occur after rapid ascent to a high-altitude environment and can lead to other pathological changes, researchers from China report, a…

Read the full story
Load More